Is Immunovant, Inc. (IMVT) a Buy, Sell, or Hold?
Immunovant, Inc.
NASDAQ:IMVT
$38.77 USD
$0.07 (0.18%)
- Volume
- 762.11K
- Average Volume
- 1.95M
- Market Capitalization
- $7.96B
- P/E Ratio
- -13.95
- Dividend Yield
- 0.00%
- Price Target
- $40.00
- Year High
- $41.23
- Year Low
- $14.32
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $9.09
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Eric Venker |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | IMVT |
| CUSIP | 45258J102 |
| CIK | 0001764013 |
| Web | https://immunovant.com |
| Phone | 917 580 3099 |
| Currency | USD |
| Employees | 315 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 9.09 |
| Quick Ratio | 9.09 |
| Cash Ratio | 8.64 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -2.00 |
| Price / Cash Flow | -19.54 |
| Price / Book | 9.26 |
Price Target and Rating
| Average Stock Price Forecast | $40.00 |
| High Stock Price Forecast | $40.00 |
| Low Stock Price Forecast | $40.00 |
| Forecast Upside/Downside | -3.07% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 23 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.77 |
| Trailing P/E Ratio | -13.95 |
| PEG Ratio | 7.03 |
| P/E Growth | 7.03 |
| Net Income | $-505.61M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -68.16% |
| Return on Assets | -52.83% |
Financials Score
| AltmanZ Score | 42.42 |
| Piotroski Score | 1.00 |
| Working Capital | 844.4M |
| Total Assets | 957.01M |
| Ebit | -505.39M |
| Market Cap | 7.95B |
| Total Liabilities | 104.42M |
Poll Results
About Immunovant, Inc. (NASDAQ:IMVT) Stock
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidi ... ary under the umbrella of Roivant Sciences Ltd.
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
2026-06-19 12:31:17
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
2026-06-12 11:11:00
IMVT shares climb as IMVT-1402 posts encouraging data, advances across autoimmune diseases and benefits from a cash runway extending through launch.
Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential
2026-05-25 06:27:31
Immunovant's underlying bull case has now moved away from batoclimab and toward IMVT-1402. This newer asset has encouraging data for difficult-to-treat RA. By week 16, 72.7% of hard-to-treat RA patients had good responses with IMVT-1402. IMVT also has a solid balance sheet this time around. And management believes its runway is sufficient through their next readouts.
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy
2026-05-21 13:09:35
Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant's IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis, with ACR20/50/70 rates of 72.7%, 54.5%, and 35.8%, respectively. ROIV's financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to profitability.
These Analysts Increase Their Forecasts On Immunovant After Q4 Results
2026-05-21 12:07:14
Immunovant Inc (NASDAQ:IMVT) on Wednesday posted a wider fourth‑quarter loss than analysts expected.
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data
2026-05-21 10:20:56
Immunovant stock jumps 35% as strong early IMVT-1402 data in rheumatoid arthritis boosts confidence despite a wider Q4 loss.
Immunovant Stock Surges Despite Disappointing Earnings Miss
2026-05-20 13:09:06
Immunovant Inc (NASDAQ:IMVT) shares are trading higher on Wednesday even though the company posted a wider fourth‑quarter loss than analysts expected.
Immunovant Q4 Earnings Call Highlights
2026-05-20 10:08:52
Roivant executives used the company's fourth-quarter and fiscal-year earnings call to highlight new clinical data from its development portfolio, upcoming readouts and its strengthened balance sheet following a settlement with Moderna.
Frequently Asked Questions
-
What is the current Immunovant, Inc. (IMVT) stock price?
-
Immunovant, Inc.(NASDAQ:IMVT) stock price is $38.77 in the last trading session. During the trading session, IMVT stock reached the peak price of $41.23 while $14.32 was the lowest point it dropped to. The percentage change in IMVT stock occurred in the recent session was 0.18% while the dollar amount for the price change in IMVT stock was $0.07.
-
IMVT's industry and sector of operation?
-
The NASDAQ listed IMVT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IMVT?
-
Christine Blodgett | Senior Vice President of Human Resources
Andy Deig | Senior Vice President of Strategic Finance
Eric Venker | Chief Executive Officer & Director
Luciano Pollastrini | Senior Vice President of CMC Technical Operations
Becky Merlina | Senior VP & Global Head of Quality -
How many employees does IMVT have?
-
Number of IMVT employees currently stands at 315. IMVT operates from 320 West 37th Street, New York City, NY 10018, US.
-
Link for IMVT official website?
-
Official Website of IMVT is: https://immunovant.com
-
How do I contact IMVT?
-
IMVT could be contacted at phone #917 580 3099 and can also be accessed through its website. IMVT operates from 320 West 37th Street, New York City, NY 10018, US.
-
How many shares of IMVT are traded daily?
-
The average number of IMVT shares traded daily for last 3 months was 1.95M.
-
What is the market cap of IMVT currently?
-
The market value of IMVT currently stands at $7.96B with its latest stock price at $38.77